19 June 2013
Keywords: hra, pharma, licensing, deal, preglem, ulipristal, paris
Article | 10 December 2007
Paris, France-based HRA Pharma, which is developing medicines and products for women's health and endocrine disease, has entered into a
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 July 2007
2 July 2007
18 June 2013
© 2013 thepharmaletter.com